Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency
- PMID: 30357024
- PMCID: PMC6196777
- DOI: 10.5114/pm.2018.78558
Signs and symptoms, evaluation, and management of genitourinary tract consequences of premature ovarian insufficiency
Abstract
Premature ovarian insufficiency (POI) occurs in 1% of women under 40 years old. Hypoestrogenism associated with this condition may result in vaginal atrophy and urine incontinence, called genitourinary syndrome. The symptoms include: vaginal dryness, irritation, dyspareunia, and dysuria. There is relative lack of studies on the occurrence and treatment of genitourinary problems in women with POI. Prevalence rates vary from 17 to 54% depending on cause, duration of oestrogen depletion, and the treatment used. Patients with POI gain lower scores in tests measuring vaginal health or sexual function in comparison to healthy peers. Hormonal treatment in premature ovarian insufficiency is recommended until the natural age of menopause. The vaginal route of oestrogen administration is supposed to be the criterion standard in treating genitourinary symptoms. Androgen supplementation is not routinely recommended.
Keywords: genitourinary syndrome; oestrogen therapy; premature ovarian insufficiency.
Similar articles
-
Premature ovarian insufficiency: the context of long-term effects.J Endocrinol Invest. 2016 Sep;39(9):983-90. doi: 10.1007/s40618-016-0467-z. Epub 2016 Apr 18. J Endocrinol Invest. 2016. PMID: 27091671 Free PMC article. Review.
-
Consequences of premature ovarian insufficiency on women's sexual health.Prz Menopauzalny. 2018 Sep;17(3):127-130. doi: 10.5114/pm.2018.78557. Epub 2018 Sep 30. Prz Menopauzalny. 2018. PMID: 30357022 Free PMC article. Review.
-
Premature ovarian insufficiency - hormone replacement therapy and management of long-term consequences.Prz Menopauzalny. 2018 Sep;17(3):135-138. doi: 10.5114/pm.2018.78559. Epub 2018 Sep 30. Prz Menopauzalny. 2018. PMID: 30357030 Free PMC article. Review.
-
Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy.Am J Obstet Gynecol. 2020 Feb;222(2):103-113. doi: 10.1016/j.ajog.2019.08.043. Epub 2019 Aug 29. Am J Obstet Gynecol. 2020. PMID: 31473229 Review.
-
Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.Maturitas. 2014 Nov;79(3):349-54. doi: 10.1016/j.maturitas.2014.07.013. Epub 2014 Aug 19. Maturitas. 2014. PMID: 25179577
Cited by
-
Health-related quality-of-life among patients with premature ovarian insufficiency: a systematic review and meta-analysis.Qual Life Res. 2020 Jan;29(1):19-36. doi: 10.1007/s11136-019-02326-2. Epub 2019 Oct 16. Qual Life Res. 2020. PMID: 31620985 Free PMC article.
-
Primary ovarian insufficiency: update on clinical and genetic findings.Front Endocrinol (Lausanne). 2024 Sep 26;15:1464803. doi: 10.3389/fendo.2024.1464803. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39391877 Free PMC article. Review.
References
-
- Simon J. Non-estrogen based treatments for vaginal atrophy. Maturitas. 2015;81:106.
-
- Kokot-Kierepa M, Bartuzi A, Kulik-Rechberger B, et al. Local estrogen therapy – clinical implications – 2012 update. Ginekol Pol. 2012;83:772–777. - PubMed
-
- Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol. 2016;215:704–711. - PubMed
-
- Piccioni P, Scirpa P, D’Emilio I, et al. Hormonal replacement therapy after stem cell transplantation. Maturitas. 2004;49:327–333. - PubMed
-
- Leining MG, Gelber S, Rosenberg R, et al. Menopausal-type symptoms in young breast cancer survivors. Ann Oncol. 2006;17:1777–1782. - PubMed
Publication types
LinkOut - more resources
Full Text Sources